shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > Lifestyle News > Health And Fitness News > Article > Protein map opens avenues for new cancer drugs

Protein 'map' opens avenues for new cancer drugs

Updated on: 27 September,2014 08:48 AM IST  | 
IANS |

Scientists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped.

Protein 'map' opens avenues for new cancer drugs

London: Scientists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped.


The scientists hope their findings will help them to design drugs that could target the enzyme - known as N-myristoyltransferase (NMT) - and potentially lead to new treatments for cancer and inflammatory conditions.


They have already identified a molecule that blocks NMT's activity, and have identified specific protein substrates where this molecule has a potent impact.


"We now have a much fuller picture of how NMT operates and more importantly, how it can be inhibited than ever before. This is the first time that we have been able to look in molecular detail at how this potential drug target works within an entire living cancer cell," explained lead researcher Ed Tate, professor at Imperial College London, department of chemistry.

The team used living human cancer cells to identify more than 100 proteins that NMT modifies -with almost all these proteins being identified for the very first time in their natural environment.

NMT makes irreversible changes to proteins and is known to be involved in a range of diseases including cancer, epilepsy and Alzheimer's disease.

The study appeared in the journal Nature Communications.

 

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK